Endometrial cancer is one of the three most common gynecological malignant tumors in women, with the incidence rate ranking first among gynecological malignant tumors in developed countries and second only to cervical cancer in China. In recent years, the incidence of endometrial cancer has shown a trend of rejuvenation, with 3%-14% of women under the age of 40, and with the gradual postponement of women’s childbearing age, the proportion of diseases that can affect fertility, such as polycystic ovary syndrome, obesity and abnormal ovarian function, increases year by year. The survey shows that up to 70% of endometrial cancer patients of childbearing age are still infertile at the time of diagnosis, and the treatment of early endometrial cancer is in principle staged surgery including total hysterectomy with both adnexa, although the 5-year survival rate is over 93%. However, it is difficult for women who have not had children to undergo the procedure. Some patients have a strong desire to preserve their reproductive function. Is it feasible for endometrial cancer patients to get pregnant? After years of clinical research and practice, the world’s first report on the successful application of high-efficiency progestin in the treatment of endometrial cancer to preserve fertility was published in 1961, bringing a ray of hope to patients with endometrial cancer of childbearing age who have not had children. However, not all patients with endometrial cancer of childbearing age can preserve their reproductive function. The feasibility of preserving reproductive function can only be initially achieved if the following conditions are met: 1) young ≤ 40 years old who desire to preserve reproductive function; 2) pathologically confirmed as stage IA, highly differentiated, progesterone receptor positive type I endometrioid adenocarcinoma; 3) ultrasound and MRI examination excluding myometrial infiltration, lymph nodes and distant metastases and lymph node and distant metastasis and ovarian tumor; 4. normal serum marker CA125 level (<35IU/ml); 5. exclude abnormal cardiopulmonary function, acute liver and kidney function injury, coagulation dysfunction and other systemic diseases; 6. exclude family history of hereditary non-polyposis colorectal cancer, previous history of other tumor occurrence or combination of tumors in other sites; 7. follow-up can be guaranteed. Patients who do not meet the above conditions should follow the doctor's advice and treat according to the principles of endometrial cancer treatment.